Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation

Table 3 Subgroup analysis for all-cause mortality: DOACs vs. VKAs use in post matched cohort

Factor	Subgroup	n	HR	95% CI	P value	Interaction P value
DOACs vs. VKAs	Total	228	0.526	0.284–0.974	0.041	–
Age	≥ 70	126	0.604	0.299–1.219	0.159	0.537
Age	< 70	102	0.331	0.091–1.206	0.094	0.537
Sex	Male	159	0.569	0.287–1.127	0.106	0.809
Sex	Female	69	0.539	0.108–2.685	0.451	0.809
NYHA class	I, II	222	0.561	0.301-1.044	0.068	0.978
NYHA class	III, IV	6	0.024	0.000-397.4	0.540	0.978
BNP	>median	114	0.341	0.115-1.012	0.053	0.168
BNP	<median	114	0.690	0.319-1.489	0.344	0.168
LVEF	Reduced	127	0.676	0.312–1.465	0.321	0.245
LVEF	Preserved	101	0.366	0.132–1.014	0.053	0.245
Ischemic etiology	Present	63	0.926	0.319–2.002	0.466	0.269
Ischemic etiology	Absent	165	0.435	0.207–0.915	0.028	0.269
Diabetes	Present	92	0.693	0.302–1.594	0.388	0.364
Diabetes	Absent	136	0.401	0.159–1.011	0.053	0.364
CKD	Present	131	0.598	0.302–1.185	0.141	0.994
CKD	Absent	97	0.667	0.152–2.931	0.591	0.994
Anemia	Present	106	0.474	0.215–1.044	0.064	0.498
Anemia	Absent	122	0.729	0.251–2.112	0.560	0.498
RAS inhibitors	Present	188	0.664	0.336–1.313	0.239	0.171
RAS inhibitors	Absent	40	0.187	0.041–0.861	0.031	0.171
β-blockers	Present	186	0.564	0.288–1.106	0.096	0.389
β-blockers	Absent	42	0.293	0.061–1.394	0.123	0.389
Diuretics	Present	166	0.630	0.333–1.191	0.155	0.475
Diuretics	Absent	62	0.452	0.041–4.992	0.517	0.475
Antiplatelet agents	Present	97	0.863	0.386–1.931	0.720	0.117
Antiplatelet agents	Absent	131	0.295	0.109–0.796	0.016	0.117

DOACs direct oral anticoagulants, VKAs Vit K antagonists, NYHA New York Heart Association, BNP B-type natriuretic peptide, LVEF left ventricular ejection fraction, CKD chronic kidney disease, RAS rennin-angiotensin-aldosterone system

ISSN: 1471-2261